

**2003-2008
GRANT RECIPIENTS**

2007 Awards

2-Year Mantle Cell Correlative Awards

Thomas M. Habermann, MD; *Mayo Clinic College of Medicine, Rochester, MN*
“Genetic Predictors of Prognosis in Mantle Cell Lymphoma”

Ronald Levy, MD; *Stanford University, Stanford, CA*
“BCR Signal Transduction in Mantle Cell Lymphoma Patients Receiving a Syk Kinase Inhibitor”

Christiane Pott, MD; *University Hospital Schleswig-Holstein, Kiel, Germany*
“Minimal Residual Disease (MRD): Optimization and Validation of Quantification Techniques”

Geoffrey I. Shapiro, MD, PhD; *Dana-Farber Cancer Institute, Boston, MA*
“Pharmacodynamic Studies of Flavopiridol and PDO332991 in Mantle Cell Lymphoma”

Wendy Stock, MD; *The University of Chicago, Chicago, IL*
“Strategies to Eradicate Minimal Residual Disease in Mantle Cell Lymphoma”

3-Year Mantle Cell Awards

Robert Baiocchi, MD, PhD; *The Ohio State University, Columbus, OH*
“Targeting HDAC and Protein Arginine Methyltransferase 5 Enzymes in Mantle Cell Lymphoma”

Steven H. Bernstein, MD; *James P. Wilmot Cancer Center, University of Rochester, Rochester, NY*
“Triterpenoids as Novel Therapeutic Agents for the Treatment of Mantle Cell Lymphoma”

Martin Dreyling, MD, PhD; *University Hospital Grosshadern/LMU, Munich, Germany*
“European MCL Network: Molecular Targeted Treatment Options and Individual Patient Risk Factors”

Ajay K. Gopal, MD; *Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA*
“Anti-CD45 Radioimmunotherapy for Mantle Cell Lymphoma”

Timothy C. Greiner, MD; *University of Nebraska Medical Center, Omaha, NE*
“Methylation Analysis in an International Group of Mantle Cell Lymphomas”

Pedro Jares, PhD; *IDIBAPS, University of Barcelona, Barcelona, Spain*
“Identification of Tumor Suppressor Genes, Epigenetic Portrait, and Genotyping of mantle Cell Lymphoma”

Shigeki Miyamoto, PhD; *University of Wisconsin School of Medicine and Public Health, Madison, WI*
“Targeting NF- κ B Activation Mechanisms for MCL Drug Development”

Oliver W. Press, MD, PhD; *Fred Hutchinson Cancer Research Center, Univ. of Washington, Seattle, WA*
“Optimizing Adoptive T-Cell Immunotherapy for Mantle Cell Lymphoma”

Leticia Quintanilla-Martinez, MD; *Institute of Pathology, GSF Research Center for Environment and Health, Oberschleissheim, Germany*

“Relevance of Cyclin D1 Isoforms Expression for the Pathogenesis of Mantle Cell Lymphoma (MCL)”

2005 Awards

3- Year Mantle Cell Awards

Joseph Bertino MD; *The Cancer Institute of New Jersey, New Brunswick, NJ*

“Successful Expansion of Umbilical Cord Blood Stem Cells”

Tulin Budak-Alpdogan, MD and Joseph Bertino MD; *The Cancer Institution Of New Jersey, New Brunswick, NJ*

“Post-Transplant High Dose MTX/ARA-C consolidation: A Drug Resistance Gene Transfer Strategy for Myeloprotection”

Elias Campo, MD, *University of Barcelona, Barcelona ,Spain and Andreas Rosenwald, MD;* *University of Wuerzburg, Germany*

“Molecular mechanisms associated with clinical progression and drug resistance in MCL”

Elliot Epner, MD, PhD; *Oregon Health and Science University, Portland, OR*

“Turning Cyclin D1 on and off in mantle cell lymphoma”

Shantaram Joshi, PhD; *University of Nebraska Medical Center, Omaha, NE*

“Optimizing Dendritic Cell-Based Therapy for Mantle Cell Lymphoma”

Timothy W. McKeithan MD, PhD and John Chan, MD; *University of Nebraska Medical Center, Omaha, NE*

“Screening with siRNA libraries to identify potential therapeutic targets for MCL”

Louis M Staudt, MD, PhD; *National Cancer Institute, Bethesda, MD*

“Identification of Therapeutic Targets in Mantle Cell Lymphoma Using an RNA Interference Library Screen”

2004 Awards

3- Year Mantle Cell Awards

Sophie Dessureault, MD, PhD; *H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL*

“A phase one trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease”

Johannes Drach, MD; *University Hospital Vienna, Austria*

“Growth control of mantle cell lymphoma by the addition of thalidomide to standard treatment”

Martin Dreyling, PD, MD; *University Hospital Grosshadern/LMU Munich, Germany*

“Evaluation of new therapeutic options and identification of molecular risk factor”

Stephen J. Forman, MD; *City of Hope Medical Center, Duarte, CA*

“Targeting minimal disease after autologous hematopoietic stem-cell transplant for mantle cell lymphoma by adoptive transfer of CD-19-specific T cells”

Timothy C. Greiner, MD; *University of Nebraska Medical Center, Omaha, NE*

“Methylation analysis in mantle cell lymphoma using an oligonucleotide microarray”

Owen O’Connor, MD, PhD; *Memorial Sloan-Kettering Cancer Center, New York, NY*

“A translational approach for the discovery and evaluation of novel drugs for the treatment of mantle cell lymphoma”

Louis M. Staudt; *National Institute of Health, Bethesda, MD*

“Gene expression profiling in mantle cell lymphoma”

Roger Strair, MD, PhD; *UMDNJ – The Cancer Institute of New Jersey, New Brunswick, NJ*

“Translational Research in Mantle Cell Lymphoma”

2003 Awards

3-Year Mantle Cell Awards

Richard E. Champlin, MD; *MD Anderson Cancer Center, Houston, TX*

“Separation of graft vs. lymphoma from graft vs. host disease using antithird party cytotoxic t-cell for treatment of MCL”

Richard J. Ford, MD, PhD; *MD Anderson Cancer Center, Houston, TX*

“Molecular and biological approaches for targeting new therapies in MCL”

Randy D. Gascoyne, MD, FRCPC; *British Columbia Cancer Agency, Vancouver, British Columbia, Canada*

“New Molecular Targets in Mantle Cell Lymphoma”

Ajay K. Gopal, MD; *The University of Washington, Seattle, WA*

“High-dose radioimmunotherapy transplant conditioning regimens for relapsed or refractory MCL”

Issa Khouri, MD; *MD Anderson Cancer Center, Houston, TX*

“Allogeneic stem cell with Rituximab-containing nonablative conditioning regimen for advanced/recurrent MCL”

John P. Leonard, MD; *Weill Medical College of Cornell University, New York, NY*

“Angiogenesis and anti-angiogenic therapy in MCL”

Jonathan Said, MD; *University of California, Los Angeles, CA*

“PIM1 in the pathogenesis of MCL: Functional collaboration with cyclin D1, potential therapeutic target”

Geoffrey I. Shapiro, MD, PhD; *Dana Farber Cancer Institute, Boston, MA*

“Cyclin-dependent kinase inhibitors in MCL”

Michael E. Williams, MD, FACP; *University of Virginia, VA*

“Mechanisms of response and resistance to monoclonal antibody therapy in a preclinical model and in patients with MCL”